Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by State Street Corp

State Street Corp lifted its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 3.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,000,998 shares of the biopharmaceutical company’s stock after purchasing an additional 33,496 shares during the period. State Street Corp’s holdings in Regulus Therapeutics were worth $1,572,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RGLS. Bank of New York Mellon Corp purchased a new position in Regulus Therapeutics in the 2nd quarter worth approximately $352,000. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics in the second quarter valued at approximately $136,000. Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 56.4% during the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 42,600 shares in the last quarter. SG Americas Securities LLC acquired a new position in Regulus Therapeutics during the third quarter worth $33,000. Finally, Creative Planning purchased a new stake in Regulus Therapeutics in the 3rd quarter valued at $26,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Trading Up 5.3 %

NASDAQ RGLS opened at $1.58 on Thursday. The stock has a fifty day simple moving average of $1.54 and a 200-day simple moving average of $1.64. The stock has a market cap of $103.49 million, a PE ratio of -1.48 and a beta of 1.61. Regulus Therapeutics Inc. has a twelve month low of $1.08 and a twelve month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Research analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on RGLS shares. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.